- Published on
Emergency and Acute Medicine – Beta-Blocker Poisoning
Foundational Concepts And Mechanism
Under normal physiology, β1-adrenergic receptor stimulation activates adenyl cyclase, converting ATP to cyclic AMP. Cyclic AMP activates protein kinase, leading to phosphorylation of sarcoplasmic reticulum proteins and release of intracellular calcium, which drives excitation–contraction coupling. β-blockers inhibit this pathway, resulting in reduced myocardial contractility and slowed conduction. Some agents possess membrane-stabilizing (sodium channel–blocking) activity that can widen the QRS complex, while others prolong the QTc interval and predispose to ventricular dysrhythmias. Certain β-blockers exhibit intrinsic sympathomimetic (partial agonist) activity. Lipophilic agents such as propranolol, metoprolol, and labetalol readily cross the blood–brain barrier and produce central nervous system toxicity.
Clinical Presentation
Cardiovascular manifestations dominate and include hypotension, bradycardia, conduction delays, varying degrees of heart block, heart failure, electrical–mechanical dissociation, and loss of β-selectivity in overdose. Neurologic effects include coma and seizures, particularly with lipophilic agents. Pulmonary findings may include bronchospasm and pulmonary edema. Metabolic derangements include hypoglycemia, especially in children and patients with limited glycogen stores.
History And Examination
History should assess for medication errors, intentional overdose or suicidal intent, and potential pediatric exposures. Physical examination typically reveals hypotension, bradycardia, and dysrhythmias.
Initial Evaluation
In cases of unknown ingestion, β-blocker toxicity should be suspected in patients presenting with unexplained bradycardia and hypotension. Electrocardiography may reveal sinus bradycardia, first-, second-, or third-degree atrioventricular block, and conduction delays. Laboratory studies include complete blood count, electrolytes, renal function, serum glucose, and toxicology screening when co-ingestants are suspected.
Diagnostic Considerations
The differential diagnosis includes calcium-channel blocker toxicity, clonidine toxicity, digitalis poisoning, and acute myocardial infarction complicated by heart block.
Prehospital And Early Management
Suspected overdose warrants transport of pill bottles when available. Early priorities include airway protection based on mental status, supplemental oxygen, intravenous access with isotonic fluids, continuous hemodynamic monitoring, bedside glucose assessment with prompt correction of hypoglycemia, and administration of naloxone and thiamine for altered mental status. Seizures should be treated with benzodiazepines.
Therapeutic Goals And Emergency Treatment
Management aims to maintain a heart rate above 60 beats per minute, systolic blood pressure above 90 mm Hg, adequate urine output, and improving mental status. Gastrointestinal decontamination with activated charcoal may be beneficial, particularly when co-ingestants are involved. Gastric lavage may be considered within one hour of ingestion, though propranolol may cause esophageal spasm and complicate tube placement. Syrup of ipecac is contraindicated.
Atropine is the initial agent for bradycardia, though response rates are limited. Glucagon is the preferred first-line antidote for β-blocker–induced hemodynamic instability when atropine is ineffective, as it increases cyclic AMP via a non-β-receptor pathway. Nausea and vomiting are common adverse effects. Intravenous fluids should be administered cautiously, with invasive monitoring considered to guide volume resuscitation.
Amrinone, a phosphodiesterase inhibitor, increases cyclic AMP and inotropy and may be used alongside glucagon for persistent bradycardia. Vasopressors are indicated for refractory hypotension, recognizing that higher doses may be required due to β-receptor blockade. Isoproterenol may be titrated for heart rate and blood pressure, while epinephrine provides combined α- and β-agonist effects and is preferred if blood pressure fails to respond. High-dose dopamine is another option.
Sodium bicarbonate is reserved for patients with QRS widening greater than 100 ms due to sodium channel blockade. Electrical pacing is considered when pharmacologic therapy fails. Advanced or experimental therapies, undertaken in consultation with a poison center, include high-dose insulin euglycemia therapy to enhance myocardial metabolism and intravenous lipid emulsion therapy. Hemodialysis may be beneficial for water-soluble agents such as nadolol, atenolol, and sotalol.
Medication Summary
Supportive care includes isotonic fluids and glucose supplementation as needed. Glucagon remains central for hemodynamic instability, with vasopressors added as required. Sodium bicarbonate is used selectively for wide-complex dysrhythmias, and hemodialysis is reserved for specific agents.
Disposition And Follow-Up
Intensive care admission is required for patients with decreased consciousness, bradycardia, hypotension, or conduction abnormalities. Extended observation for at least 24 hours is recommended for long-acting or sustained-release formulations. Patients may be discharged if asymptomatic 8–10 hours after ingestion of immediate-release preparations. Psychiatric evaluation is necessary for intentional overdoses, and poison-prevention counseling should be provided for caregivers in pediatric cases.
Clinical Priorities And Common Pitfalls
β-blocker toxicity should be promptly considered in any patient with unexplained bradycardia and hypotension. Wide-complex dysrhythmias signal sodium channel blockade and warrant sodium bicarbonate therapy. Early recognition and aggressive, mechanism-based treatment are critical to improving outcomes.
Foundational Concepts And Mechanism
Under normal physiology, β1-adrenergic receptor stimulation activates adenyl cyclase, converting ATP to cyclic AMP. Cyclic AMP activates protein kinase, leading to phosphorylation of sarcoplasmic reticulum proteins and release of intracellular calcium, which drives excitation–contraction coupling. β-blockers inhibit this pathway, resulting in reduced myocardial contractility and slowed conduction. Some agents possess membrane-stabilizing (sodium channel–blocking) activity that can widen the QRS complex, while others prolong the QTc interval and predispose to ventricular dysrhythmias. Certain β-blockers exhibit intrinsic sympathomimetic (partial agonist) activity. Lipophilic agents such as propranolol, metoprolol, and labetalol readily cross the blood–brain barrier and produce central nervous system toxicity.
Clinical Presentation
Cardiovascular manifestations dominate and include hypotension, bradycardia, conduction delays, varying degrees of heart block, heart failure, electrical–mechanical dissociation, and loss of β-selectivity in overdose. Neurologic effects include coma and seizures, particularly with lipophilic agents. Pulmonary findings may include bronchospasm and pulmonary edema. Metabolic derangements include hypoglycemia, especially in children and patients with limited glycogen stores.
History And Examination
History should assess for medication errors, intentional overdose or suicidal intent, and potential pediatric exposures. Physical examination typically reveals hypotension, bradycardia, and dysrhythmias.
Initial Evaluation
In cases of unknown ingestion, β-blocker toxicity should be suspected in patients presenting with unexplained bradycardia and hypotension. Electrocardiography may reveal sinus bradycardia, first-, second-, or third-degree atrioventricular block, and conduction delays. Laboratory studies include complete blood count, electrolytes, renal function, serum glucose, and toxicology screening when co-ingestants are suspected.
Diagnostic Considerations
The differential diagnosis includes calcium-channel blocker toxicity, clonidine toxicity, digitalis poisoning, and acute myocardial infarction complicated by heart block.
Prehospital And Early Management
Suspected overdose warrants transport of pill bottles when available. Early priorities include airway protection based on mental status, supplemental oxygen, intravenous access with isotonic fluids, continuous hemodynamic monitoring, bedside glucose assessment with prompt correction of hypoglycemia, and administration of naloxone and thiamine for altered mental status. Seizures should be treated with benzodiazepines.
Therapeutic Goals And Emergency Treatment
Management aims to maintain a heart rate above 60 beats per minute, systolic blood pressure above 90 mm Hg, adequate urine output, and improving mental status. Gastrointestinal decontamination with activated charcoal may be beneficial, particularly when co-ingestants are involved. Gastric lavage may be considered within one hour of ingestion, though propranolol may cause esophageal spasm and complicate tube placement. Syrup of ipecac is contraindicated.
Atropine is the initial agent for bradycardia, though response rates are limited. Glucagon is the preferred first-line antidote for β-blocker–induced hemodynamic instability when atropine is ineffective, as it increases cyclic AMP via a non-β-receptor pathway. Nausea and vomiting are common adverse effects. Intravenous fluids should be administered cautiously, with invasive monitoring considered to guide volume resuscitation.
Amrinone, a phosphodiesterase inhibitor, increases cyclic AMP and inotropy and may be used alongside glucagon for persistent bradycardia. Vasopressors are indicated for refractory hypotension, recognizing that higher doses may be required due to β-receptor blockade. Isoproterenol may be titrated for heart rate and blood pressure, while epinephrine provides combined α- and β-agonist effects and is preferred if blood pressure fails to respond. High-dose dopamine is another option.
Sodium bicarbonate is reserved for patients with QRS widening greater than 100 ms due to sodium channel blockade. Electrical pacing is considered when pharmacologic therapy fails. Advanced or experimental therapies, undertaken in consultation with a poison center, include high-dose insulin euglycemia therapy to enhance myocardial metabolism and intravenous lipid emulsion therapy. Hemodialysis may be beneficial for water-soluble agents such as nadolol, atenolol, and sotalol.
Medication Summary
Supportive care includes isotonic fluids and glucose supplementation as needed. Glucagon remains central for hemodynamic instability, with vasopressors added as required. Sodium bicarbonate is used selectively for wide-complex dysrhythmias, and hemodialysis is reserved for specific agents.
Disposition And Follow-Up
Intensive care admission is required for patients with decreased consciousness, bradycardia, hypotension, or conduction abnormalities. Extended observation for at least 24 hours is recommended for long-acting or sustained-release formulations. Patients may be discharged if asymptomatic 8–10 hours after ingestion of immediate-release preparations. Psychiatric evaluation is necessary for intentional overdoses, and poison-prevention counseling should be provided for caregivers in pediatric cases.
Clinical Priorities And Common Pitfalls
β-blocker toxicity should be promptly considered in any patient with unexplained bradycardia and hypotension. Wide-complex dysrhythmias signal sodium channel blockade and warrant sodium bicarbonate therapy. Early recognition and aggressive, mechanism-based treatment are critical to improving outcomes.
0 Comments
